Oxford Nanopore's London IPO pays off
UK biotech company's 43% pop dispels "the idea you cannot IPO a life sciences company in the UK," said a source
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts